WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke DRIVEN BY OUR PROMISE wurde als Wortmarke am 22.06.2017 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1387078 |
| Länder | 
|
| Basismarke |
Nr. 87168219,
12. September 2016
|
| Anmeldedatum | 22. Juni 2017 |
| Ablaufdatum | 27. Juli 2020 |
Markeninhaber
1020 First Avenue
King of Prussia PA 19406
US
King of Prussia PA 19406
US
Markenvertreter
Hostatostr. 26
65929 Frankfurt am Main
DE
Waren und Dienstleistungen
01
Adjuvants for use in the manufacture of human vaccines and
pharmaceutical preparations; excipients in the form of
medium components and product stabilizers for use in the
manufacture of pharmaceutical preparations
05
Pharmaceutical preparations and substances for the treatment
and/or prevention of blood or bleeding disorders; vaccines;
blood products in this class, namely, blood plasma, and
reagent blood cells for medical diagnostic purposes;
products derived from blood and products derived from
recombinant DNA technology, namely, immunoglobulins, human
albumin, blood clotting factors, plasma volume expanders,
blood proteins for therapeutic use; serums, namely,
anti-venoms; medicated serums for the treatment of blood or
bleeding disorders; test kits in the class, namely, in-vitro
diagnostic reagent test kits comprised of medical diagnostic
reagents for use in detecting cell mediated immune response;
pharmaceutical preparations and substances, namely, RhD
reagents for the detection of specific antigens or in blood
typing; pharmaceutical preparations, namely, reagent red
blood cells used to detect antibodies or IgG subtypes;
pharmaceutical preparations, namely, monoclonal and
polyclonal antibodies; pharmaceutical preparations, namely,
clinical medical reagents for the typing and detection of
specific blood cells, and the detection of relevant
compliment components and immunoglobulin subtypes;
antibodies for use in the treatment of infectious diseases,
cancer, and autoimmune diseases; drug delivery agents
consisting of molecular carrier compounds and other
compounds that facilitate delivery of a wide range of
pharmaceuticals and drugs; immunomodulators for alteration
of immune response in humans
10
Surgical and medical apparatus and instruments for use in
intravenous administration of pharmaceutical and blood
products for the treatment of blood or bleeding disorders
and vaccines; analysis apparatus and instruments in this
class, namely, apparatus for blood analysis
16
Printed matter and publications, namely, printed
instructional material and magazines featuring information
in the fields of pharmaceutical products, vaccines, blood,
blood products, bleeding disorders, blood fractionations,
rhesus prophylaxis and human autoimmune disorders; printed
instructional and teaching materials in the field of
pharmaceutical products, vaccines, blood, blood products,
bleeding disorders, blood fractionations, rhesus prophylaxis
and human autoimmune disorders; brochures, pamphlets and
informational flyers in the field of pharmaceutical
products, vaccines, blood, blood products, bleeding
disorders, blood fractionations, rhesus prophylaxis and
human autoimmune disorders; posters; stationery
39
Transport and storage of goods, namely, transport,
distribution and storage of blood plasma; transport logistic
services, namely, supply chain logistics services in the
nature of transportation and delivery of goods by air, rail,
ship or truck and consulting services concerning all of the
above
40
Treatment of biological products, namely fractionation of
blood custom manufacturing of biological products, namely,
blood; processing of human blood plasma, namely, removing
whole blood and separating red blood cells from plasma
42
Medical laboratory services, namely, scientific testing and
screening services for testing of human blood plasma for
safety and quality
44
Blood bank services; medical testing and screening services
for diagnostic or treatment purposes; medical testing of
human blood plasma for diagnostic or treatment purposes;
collection of human blood plasma; medical services, namely,
providing medical information concerning blood products,
providing medical information concerning vaccines,
anti-venoms, immunohaematology products and diagnostic
reagents; patient support services, namely, providing
medical information received by patients to patients that
can enquire about medical issues and procedures from other
patients and can relay information about their medical
experiences for support and community via an Internet-based
database; health care, namely, providing health care
information by telephone, the internet, and through the
distribution of printed matter; medical laboratory services
for the analysis of blood plasma samples taken from
patients
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 29. April 2021 | 2021/21 Gaz | US | RAW: Total Ceasing Effect |
| 29. August 2018 | 2018/35 Gaz | AU | Ablehnung |
| 03. Juli 2018 | 2018/27 Gaz | EM | Ablehnung |
| 22. Juni 2017 | 2018/3 Gaz | US | Eintragung |
ID: 141387078